Search

Your search keyword '"Rivera-Gallego, Alberto"' showing total 37 results
Start Over Author "Rivera-Gallego, Alberto"
37 results on '"Rivera-Gallego, Alberto"'

3. Inflammatory and Cardiovascular Biomarkers to Monitor Fabry Disease Progression.

Author

Alonso-Núñez, Adrián, Pérez-Márquez, Tania, Alves-Villar, Marta, Fernández-Pereira, Carlos, Fernández-Martín, Julián, Rivera-Gallego, Alberto, Melcón-Crespo, Cristina, San Millán-Tejado, Beatriz, Ruz-Zafra, Aurora, Garofano-López, Remedios, Sánchez-Martínez, Rosario, García-Payá, Elena, López-Mendoza, Manuel, Martín-Suárez, Ignacio, and Ortolano, Saida

Subjects
ANGIOKERATOMA corporis diffusum, DISEASE progression, ENZYME replacement therapy, MOLECULAR chaperones, BIOMARKERS, GALACTOSIDASES
Abstract

Fabry disease is an invalidating multisystemic disorder affecting α-Galactosidase, a rate-limiting hydrolase dedicated to lipid catabolism. Non-metabolized substrates, such as Globotriaosylceramide and its derivatives trigger the direct or indirect activation of inflammatory events and endothelial dysfunction. In spite of the efficacy demonstrated by enzyme replacement therapy or pharmacological chaperones in delaying disease progression, few studies have analyzed whether these treatments can improve the pro-inflammatory state of FD patients. Therefore, the aim of this work was to assess cytokines and cardiovascular risk-related proteins detectable in plasma from FD patients, whether treated or not with ERT, to evaluate the reliability of these markers in monitoring disease stage and treatment effects. We identified inflammatory and endothelial dysfunction markers (ADAMTS-13, TNF-α, GDF-15, MIP-1β, VEGFA, MPO, and MIC-1) that cooperate in a common pathway and are increased in FD patients' plasma samples. As shown by the assessment of these proteins over time, they can help to evaluate the risk of higher severity in FD, as well as ERT effects. Even though the analyzed proteins cannot be considered as proper biomarkers due to their non-specificity to FD, taken together they can provide a signature of reference molecules with prognostic value for early diagnosis, and evaluation of disease progression and treatment efficacy, using blood samples. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial

Author

Muñoz-Rivas, Nuria, primary, Aibar, Jesús, additional, Gabara-Xancó, Cristina, additional, Trueba-Vicente, Ángela, additional, Urbelz-Pérez, Ana, additional, Gómez-Del Olmo, Vicente, additional, Demelo-Rodríguez, Pablo, additional, Rivera-Gallego, Alberto, additional, Bosch-Nicolau, Pau, additional, Perez-Pinar, Montserrat, additional, Rios-Prego, Mónica, additional, Madridano-Cobo, Olga, additional, Ramos-Alonso, Laura, additional, Alonso-Carrillo, Jesús, additional, Francisco-Albelsa, Iria, additional, Martí-Saez, Edelmira, additional, Maestre-Peiró, Ana, additional, Méndez-Bailón, Manuel, additional, Hernández-Rivas, José Ángel, additional, and Torres-Macho, Juan, additional

Published
2022
Full Text
View/download PDF

13. Covid 19 and venous thromboembolic disease. Review on a series of patients

Author

Núñez Fernández, Manuel Jesús, Suárez Rodríguez, Beatriz, Pombo Vide, B, Mella Pérez, Carmen, Barbagelata López, C., Díaz Peromingo, José Antonio, Puerta Louro, Rubén, Rivera Gallego, Alberto, Padín Paz, Emilio Manuel, Núñez Fernández, Manuel Jesús, Suárez Rodríguez, Beatriz, Pombo Vide, B, Mella Pérez, Carmen, Barbagelata López, C., Díaz Peromingo, José Antonio, Puerta Louro, Rubén, Rivera Gallego, Alberto, and Padín Paz, Emilio Manuel

Published
2020

15. COVID 19 Y ENFERMEDAD TROMBOEMBÓLICA VENOSA. REVISIÓN DE SERIES DE CASOS.

Author

Núñez Fernández, Manuel Jes�s, primary, Padín Paz, Emilio Manuel, additional, Suárez Rodríguez, Beatriz, additional, Pombo Vide, Beatriz, additional, Mella Pérez, Carmen, additional, Barbagelata López, Cristina, additional, Díaz-Peromingo, Jos� Antonio, additional, Puerta Louro, Rub�n, additional, and Rivera Gallego, Alberto, additional

Published
2020
Full Text
View/download PDF

16. Covid 19 and venous thromboembolic disease. Review on a series of patients.

Author

Jesús Núñez-Fernández, Manuel, Manuel Padín-Paz, Emilio, Suárez-Rodrígue, Beatriz, Pombo - Vide, Beatriz, Mella-Pérez, Carmen, Barbagelata-López, Cristina, Díaz-Peromingo, José Antonio, Puerta-Louro, Rubén, and Rivera-Gallego, Alberto

Subjects
COVID-19, BLOOD coagulation disorders, INFLAMMATION, PULMONARY embolism, THROMBOPHLEBITIS, FIBRINOGEN, FIBRIN fragment D
Published
2020
Full Text
View/download PDF

17. Trombosis venosa esplácnica

Author

Pérez González, Alexandre, Montes Santiago, Julio, Rivera Gallego, Alberto, Pérez González, Alexandre, Montes Santiago, Julio, and Rivera Gallego, Alberto

Published
2018

22. High prevalence of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia

Author

Sopeña Perez-Argüelles, Bernardo, Perez Rodriguez, Maria Teresa, PORTELA ORJALES, DANIEL, Rivera Gallego, Alberto, Freire Dapena, Maria del Carmen, and Martinez Vázquez, Cesar Antonio

Subjects
Arteriovenous Malformations, Hospitalization, Hypertension, Pulmonary, Angiography, Kaplan-Meier Estimate, Echocardiography, Doppler, Follow-Up Studies, Liver Circulation
Abstract

OBJECTIVE: Hereditary hemorrhagic telangiectasia (HHT) is a vascular disorder causing mucocutaneous telangiectases and visceral arteriovenous malformations (AVMs). Pulmonary hypertension (PH) is considered an uncommon complication of HHT whose impact on the survival of these patients is currently unknown. METHODS: From January 1995 to December 2008, 29 hospitalized patients with definite HHT were included and followed until January 2011. Data on demographics, clinical symptoms and survival were recorded. PH was classified according to echocardiographic probability. RESULTS: A CT angiogram was performed in 24 of the 29 patients with HHT and AVMs were detected in 16 of them (67%): hepatic in 58%, pulmonary in 33% and spinal in 3%; 37% had both pulmonary and hepatic AVMs. Transthoracic Doppler echocardiography (TTE) was performed in 21 patients. PH was considered possible in 4 (14%) and probable in 9 (31%). The mean age at diagnosis was lower in patients with PH than in patients without PH (54±16.5 years vs 73±8.8 years, p=0.002). PH was more prevalent in patients with AVMs (56 vs. 23%, p=0.036). The mean follow-up of the entire cohort was 6±4.4 years (range: 2 months-17 years), during this time 18 patients died (62%; mean age 73±8.1 years). Patients with PH died at a younger age (68±8.4 vs. 79±2.7 years, p=0.015) than those without PH. CONCLUSIONS: PH is a severe condition that significantly reduces survival on HHT patients. PH should be suspected in all HHT patients with dyspnea and hepatic AVMs.

Published
2013

27. Autoimmune hepatitis and hepatic arteritis

Author

Gonzalez-Carrero Fojón, Joaquín, Sopeña Perez-Argüelles, Bernardo, Rivera Gallego, Alberto, Freire Dapena, Maria del Carmen, and Villaverde Alvarez, Iria

Published
2012

30. Empirical hospital treatment regimes for skin and soft tissue infections. Clinical guidelines and real empirical practice

Author

Pérez Rodríguez, María Teresa, Argibay Filgueira, Ana Belén, Nodar, A., Martínez Vidal, A, Rodríguez Gómez, A, Sousa, A, Lorenzo, R, Rivera Gallego, Alberto, Pérez Rodríguez, María Teresa, Argibay Filgueira, Ana Belén, Nodar, A., Martínez Vidal, A, Rodríguez Gómez, A, Sousa, A, Lorenzo, R, and Rivera Gallego, Alberto

Abstract

Objetivos: Existen diferentes guías de tratamiento de la infección de piel y partes blandas (IPPB), sin embargo el tratamiento de estos pacientes es muy variable. Los objetivos fueron analizar las pautas antibióticas, así como su duración en pacientes con IPPB que precisaron ingreso. Pacientes y métodos: Se revisaron los pacientes con IPPB ingresados entre enero y diciembre de 2009. Se recogieron las pautas de tratamiento antibiótico empleadas antes, durante y tras el ingreso, así como su duración. Resultados: De un total de 131 pacientes con IPPB ingresados, se identificaron 41 pautas diferentes de tratamiento antibiótico. En 61 pacientes (47%) se emplearon dos o más fármacos y en 21 (16%) antibióticos de amplio espectro. En 25 pacientes (19%) se modificó la pauta antibiótica por mala evolución y se utilizaron 16 regímenes antibióticos diferentes. En los pacientes con fracaso del tratamiento antibiótico, ni la duración del ingreso (12 ± 9.0 días vs. 14 ± 8.7 días, p = 0.31), ni la duración del tratamiento antibiótico (12 ± 8.2 días vs. 14 ± 6.8 días, p = 0.33) fueron superiores a la de aquellos en los que la respuesta al tratamiento empírico inicial fue adecuada. Al alta, 95 pacientes (73%) recibieron tratamiento antibiótico, se identificaron 25 regímenes diferentes; 22 pacientes (23%) recibieron dos o más antibióticos y antibióticos de amplio espectro se pautaron en 10 casos. Conclusiones: La IPPB es una causa creciente de hospitalización y, a pesar de existir guías recientes de tratamiento, las pautas de tratamiento antibiótico son altamente variables., Objetives: There are several clinical guidelines for the management of skin and soft tissue infections (SSTI); however, the empirical treatment of patients with this common cause of hospital admission is highly variable. The aims of this study were to determine the empirical antibiotic treatment regimes and the duration of antibiotic treatment of SSTI requiring hospitalization. Patients and methods: Cases admitted for SSTI were reviewed. We evaluated antibiotic therapy before, during and after hospitalization, as well as duration of treatment. Results: From the 131 patients, 41 different antibiotic regimes were identified. Antibiotic combinations were used in 61 patients (47%) and broadspectrum antibiotics were used in 21 patients (16%). Modification of the antibiotic regimen was required in 25 patients (19%) due to poor clinical response, and 16 different regimes were prescribed. For patients with treatment failure, neither duration of hospitalization (12 ± 9.0 days vs. 14 ± 8.7 days, p = 0.31) nor duration of antibiotic treatment (12 ± 8.2 days vs. 14 ± 6.8 days, p = 0.33) were greater than for those who responded to the initial empirical treatment. On discharge, antibiotic treatment was prescribed for 95 patients (73%), with 25 different regimes, including a combination of drugs in 22 patients (23%) and broad-spectrum antibiotics in 10. Conclusions: SSTI is an increasing cause of hospitalization and, despite recent relevant formal guidelines, management is greatly variable.

Published
2014

31. Alelos HLA DRB1 no Lupus Eritematoso Incompleto

Author

Sopeña Pérez-Argüelles, Bernardo, Rivera Gallego, Alberto, González Quintela, Arturo, Universidade de Santiago de Compostela. Facultade de Medicina e Odontoloxía. Departamento de Medicina, Maure Noia, Brenda, Sopeña Pérez-Argüelles, Bernardo, Rivera Gallego, Alberto, González Quintela, Arturo, Universidade de Santiago de Compostela. Facultade de Medicina e Odontoloxía. Departamento de Medicina, and Maure Noia, Brenda

Abstract

O lupus eritematoso sistémico é unha enfermidade multifactorial na que se sabe que participan mecanismos xenéticos. A asociación máis consistente encontrouse nos xenes do complexo maior de histocompatibilidade de clase II, en concreto nos alelos DRB1*03 e DRB1*15. Entre os pacientes atendidos en consultas de enfermidades autoinmunes hai algúns con anticorpos anti-nucleares (ANA) positivos e manifestacións clínicas suxestivas de LES, pero que non reúnen 4 criterios de clasificación, polo que son etiquetados como lupus eritematoso incompleto (LEI). Algúns destes pacientes desenvolverán LES, pero actualmente non se dispón de medios para identificalos, polo que na práctica, os LEI son seguidos en consulta durante anos. Obxectivos:O obxectivo deste estudo é caracterizar xenéticamente un grupo de pacientes con LEI e comparalos cos resultados obtidos en pacientes con LES e nu grupo control san.

Published
2014

36. Guía gallega de manejo de la trombosis asociada a cáncer. II edición

Author

Campos Balea, Begoña, Fernández Bouza, Elena, Barbagelata López, Cristina, Brozos Vázquez, Elena María, CAROU FRIEIRO, IRIA, Fernández Pérez, Isaura, Iglesias Rey, Leticia, Quindós Varela, María, Carmona Campos, Marta, Antolín Novoa, Silvia, Rivera Gallego, Alberto, and López López, Rafael

Subjects
Venous Thrombosis, guía de práctica clínica, Tumores [neoplasias] malignos (C00-C97), trombosis, Anticoagulants, Thrombosis, oncología médica, Medical Oncology, trombosis venosa, Anticoagulantes, Practice Guideline, cáncer, Thromboembolism, tromboembolia, anticoagulación, trombose, Embolia y trombosis de vena no especificada
Abstract

Esta guía práctica y sencilla, guiará en el diagnóstico y tratamiento de los pacientes con trombosis y cáncer. Pretende reducir la variabilidad en el manejo en la Comunidad Autónoma de Galicia y reducir el impacto negativo que la trombosis presenta en los pacientes con cáncer. This practical and simple guide will guide in the diagnosis and treatment of patients with thrombosis and cancer. It aims to reduce variability in management in the Autonomous Community of Galicia and reduce the negative impact that thrombosis has on cancer patients. Esta guía práctica e sinxela, guiará no diagnóstico e tratamento dos pacientes con trombose e cancro. Pretende reducir a variabilidade no manexo na Comunidade Autónoma de Galicia, e reducir o impacto negativo que a trombose presenta nos pacientes con cancro. Con el Aval de la Sociedad Oncológica de Galicia (SOG) y la Sociedade Galega de Medicina Interna (SOGAMI). Publicado en Barcelona por Bubblegum Communication Services el 25 de ocutubre de 2019. ISBN: 978-84-09-1419-4 LEO Pharma

Published
2019

37. Alelos HLA DRB1 no Lupus Eritematoso Incompleto

Author

Maure Noia, Brenda, Sopeña Pérez-Argüelles, Bernardo, Rivera Gallego, Alberto, González Quintela, Arturo, and Universidade de Santiago de Compostela. Facultade de Medicina e Odontoloxía. Departamento de Medicina

Subjects
lupus eritematoso sistémico, Alelos HLA DRB1, xenes, Investigación::32 Ciencias médicas::3299 otras especialidades medicas (especificar) [Materias]
Abstract

O lupus eritematoso sistémico é unha enfermidade multifactorial na que se sabe que participan mecanismos xenéticos. A asociación máis consistente encontrouse nos xenes do complexo maior de histocompatibilidade de clase II, en concreto nos alelos DRB1*03 e DRB1*15. Entre os pacientes atendidos en consultas de enfermidades autoinmunes hai algúns con anticorpos anti-nucleares (ANA) positivos e manifestacións clínicas suxestivas de LES, pero que non reúnen 4 criterios de clasificación, polo que son etiquetados como lupus eritematoso incompleto (LEI). Algúns destes pacientes desenvolverán LES, pero actualmente non se dispón de medios para identificalos, polo que na práctica, os LEI son seguidos en consulta durante anos. Obxectivos:O obxectivo deste estudo é caracterizar xenéticamente un grupo de pacientes con LEI e comparalos cos resultados obtidos en pacientes con LES e nu grupo control san.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results